UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Terminated
Unique ID issued by UMIN UMIN000010641
Receipt No. R000012446
Scientific Title Phase II study of multi-agent chemotherapy in patients with adult Burkitt leukemia.
Date of disclosure of the study information 2013/05/15
Last modified on 2019/03/29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Phase II study of multi-agent chemotherapy in patients with adult Burkitt leukemia.
Acronym Study of multi-agent chemotherapy in patients with adult Burkitt leukemia. (JALSG Burkitt-ALL213)
Scientific Title Phase II study of multi-agent chemotherapy in patients with adult Burkitt leukemia.
Scientific Title:Acronym Study of multi-agent chemotherapy in patients with adult Burkitt leukemia. (JALSG Burkitt-ALL213)
Region
Japan

Condition
Condition Burkitt leukemia
Classification by specialty
Hematology and clinical oncology
Classification by malignancy Malignancy
Genomic information YES

Objectives
Narrative objectives1 To evaluate safety and efficacy of Rituximab containing regimen in the treatment of newly diagnosed previously untreated adult Burkitt acute lymphoblastic leukemia.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Phase II

Assessment
Primary outcomes 3 year event free survival (EFS)
Key secondary outcomes Complete remission rate
Adverse event rate
3 year overall survival (OS), and disease free survival (DFS)

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Historical
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Rituximab combined chemotherapy
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
15 years-old <=
Age-upper limit
65 years-old >
Gender Male and Female
Key inclusion criteria 1. Recognized ALL
2. Burkitt-ALL (diagnosed by WHO Classification)
3. Age 15 to 64
4. Performance Status: 0 to 3
5. Adequate hepatic, renal and cardiac function
6. Written informed consent
Key exclusion criteria 1. Previously treated with leukapheresis
2. Congestive heart failure
3. Recent history of myocardial infarction
4. Malignant hypertension
5. Lung fibrosis
6. Interstitial pneumonitis
7. Severe comorbidity
(diabetes mellitus, infection or liver cirrhosis)
8. Positive anti-HIV antibody or HBs antigen
9. Thrombosis which need treatment
10. Psychological disorders
11. Other active neoplasms
12. Pregnant and/or lactating woman
13. Judged to be inadequate
Target sample size 21

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Kiyotoshi Imai
Organization JALSG-ALL-213 research secretariat
Division name Sapporo Hokuyu Hospital, Department of Hematology
Zip code
Address 6-6-5-1 Higashi-Sapporo, Shiroishi-ku, Sapporo
TEL 011-865-0111
Email ki-imai@hokuyu-aoth.org

Public contact
Name of contact person
1st name
Middle name
Last name Tohru Murayama
Organization JALSG-ALL-213 research secretariat
Division name Hyogo Cancer Center, Department of Hematology
Zip code
Address 13-70 kita-oji, Akashi, Hyogo
TEL 078-929-1151
Homepage URL http://www.jalsg.jp
Email tmurayam@hp.pref.hyogo.jp

Sponsor
Institute Japan Adult Leukemia Study Group
Institute
Department

Funding Source
Organization Ministry of Health, Labor and Welfare
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions JALSG参加施設
北海道  (39都道府県になります)
青森県
宮城県
秋田県
山形県
福島県
栃木県
茨城県
群馬県
埼玉県
千葉県
東京都
神奈川県
新潟県
富山県
石川県
福井県
長野県
岐阜県
静岡県
愛知県
三重県
滋賀県
京都府
大阪府
兵庫県
奈良県
島根県
岡山県
広島県
山口県
香川県
愛媛県
高知県
福岡県
長崎県
熊本県
大分県

Other administrative information
Date of disclosure of the study information
2013 Year 05 Month 15 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Terminated
Date of protocol fixation
2013 Year 03 Month 09 Day
Date of IRB
2013 Year 04 Month 22 Day
Anticipated trial start date
2013 Year 07 Month 07 Day
Last follow-up date
2023 Year 06 Month 02 Day
Date of closure to data entry
2023 Year 10 Month 02 Day
Date trial data considered complete
2024 Year 02 Month 02 Day
Date analysis concluded
2024 Year 06 Month 02 Day

Other
Other related information

Management information
Registered date
2013 Year 05 Month 03 Day
Last modified on
2019 Year 03 Month 29 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012446

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.